Advertisement
Advertisement
RARE
Ultragenyx Pharmaceutical Inc.
42.60
USD-1.88
-4.23%
Feb 21, 15:59 UTC -5
Closed
After-Market
44.74
+2.14
+5.02%
Ultragenyx Pharmaceutical Inc. Profile
About
Info & Links
CEO
Emil D. Kakkis
Headquarters
Novato, CA 94949, UNITED STATES
Industry
Sector
Website
Auditor
Ernst & Young LLP
Share holders
8
Employees
1,294
Ultragenyx Pharmaceutical Inc. Statistics
Valuation Measures
Market Capitalization2
4.13B
Enterprise Value
3.96B
Enterprise Value/EBITDA(ttm)
-7.71
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
7.30
Price to Book(mrq)
11.77
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
86.22%
Operating Margin(ttm)
-101.60%
Profit Margin(ttm)
-109.69%
Return on Equity(ttm)
-185.70%
Return on Invested Capital(ttm)
-235.35%
Return on Assets(ttm)
-38.25%
Income Statement
Revenue(ttm)
560.23M
Revenue Per Share(ttm)
6.06
Gross Profit(ttm)
483.50M
EBITDA(ttm)3
-513.05M
Net Income Available to Common(ttm)
-569.18M
Diluted EPS(ttm)
-6.34
Share Statistics
Beta (5Y Monthly)
0.60
52-Week Change
-11.01%
S&P 500 52-Week Change
20.70%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
92.50M
Dividend Yield
0.00%
Float4
86.99M
% Held by Insiders
5.80%
% Held by Institutions
97.67%
Balance Sheet
Total Cash(mrq)
610.02M
Total Cash Per Share(mrq)
6.59
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
2.81%
Quick Ratio(mrq)
2.65%
Book Value Per Share(mrq)
3.76
Cash Flow
Operating Cash Flow Per Share(ytd)
-3.50
Free Cash Flow(ytd)
-341.52M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
- 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
- 2 Market Cap is calculated using total shares outstanding and the most recent share price.
- 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
- 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement